MiniMed: Next-Generation Diabetes Platform Supports A Buy Rating
MiniMed Group Inc MMED
$18.05
▼ -0.52%
($-0.10)
⬇️ Below Yest. Low
🔥 High Short Interest
Open
$18.15
Prev Close
$18.15
Day Range
$17.66 – $18.24
52W Range
$10.65 – $20.48
Market Cap
$5.07B
Beta
-0.09
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-03-06 |
| Shares Out. | 280,840,000 |
| Phone | 13026365401 |
| Employees | 2,800 |
| Website | minimed.com ↗ |
About MiniMed Group Inc
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.
MiniMed Group Inc is a publicly traded company under the ticker symbol MMED on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)